Project Grant W81XWH2010540

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The award of $356,250 will support a two-phase project by Vasarya Therapeutics, Inc. to perform affinity maturation and liability assessment on a tool compound called VSR-H5, which has demonstrated the ability to selectively target and inhibit...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $350,000 to Adiutrix Therapeutics LLC to develop a novel anti-fibrotic compound platform to identify and develop first-in-class therapeutics targeting collagen prolyl-4 hydroxylase (C-P4H) activity. The goal is to treat tissue remodeling and fibrosis in underserved diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma skin fibrosis, kidney fibrosis, and intestinal fibrosis...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...

The University of Kentucky Research Foundation received a $698,070 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on targeting lung fibrosis using epigenetic therapy. The 4-year project, which commenced on August 15, 2024, aims to examine whether the FDA-approved EZH2 inhibitor Tazemetostat can prevent or reverse aberrant epithelial cell fate and pro-fibrotic signaling in organotypic cell cultures and in...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...

This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $1,193,262 to The Regents of the University of California, San Francisco to develop an adeno-associated virus-mediated SGPL1 gene therapy as a potential treatment for idiopathic pulmonary fibrosis (IPF). The research aims to confirm the efficacy of this gene therapy in reducing lung fibrosis and downstream profibrotic signaling, as well as optimize the therapy's...

This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...

This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $695,403 to the University of Arizona to conduct research aimed at developing new therapeutic approaches to inhibit the progression of pulmonary fibrosis. The key focus is on restoring the integrity of the lung microvasculature through nanoparticle gene therapy targeting the FOXF1 and R-RAS genes, as well as transplantation of FOXF1+CKIT+ endothelial progenitor...